Author(s): Takiar R, Nadayil D, Nandakumar A
Introduction: Recently, NCRP (ICMR), Bangalore, has published a report on Time Trends in Cancer Incidence Rates. The report also provided projected numbers of cancer cases at the India country level for selected leadingsites.
Objective: In the present paper, an attempt has been made to project cancer cases for India by sex, years and cancer groups.
Sources of data: The incidence data generated by population-based cancer registries (PBCRs) at Bangalore, Barshi, Bhopal, Chennai, Delhi and Mumbai for the years 2001-2005 formed the sources of data. In addition, the latest incidence data of North Eastern Registries for the year 2005-06 were utilized.
Methods: The crude incidence rate (CR) was considered suitable for assessing the future load of cancer cases in the country. The Linear Regression method (IARC 1991) was used to assess the time trend and the projection of rates for the periods 2010-2020. For whichever sites where trends were not found to be significant, their latest rates were taken into consideration and assumed to remain same for the period 2010-2020.
Results: The total cancer cases are likely to go up from 979,786 cases in the year 2010 to 1,148,757 cases in the year 2020. The tobacco-related cancers for males are estimated to go up from 190,244 in the year 2010 to 225,241 in the year 2020. Similarly, the female cases will go up from 75,289 in year 2010 to 93,563 in the year 2020. For the year 2010, the number of cancer cases related to digestive system, for both males and females, are estimated to be 107,030 and 86,606 respectively. For, head and neck cancers, the estimates are 122,643 and 53,148 cases, respectively. and for the lymphoid and hematopoietic system (LHS), for the year 2010, are 62,648 for males and 41,591 for females. Gynecological-related cancers are estimated to go up from 153,850 in 2010 to 182,602 in 2020. Among males and females, cancer of breast alone is expected to cross the figure of 100,000 by the year 2020.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/21133622
Author(s): GM Cragg, DJ Newman
Author(s): Kumar S, Suresh PK, Vijayababu MR, Arunkumar A, Arunakaran J
Author(s): R Baral, Chattopadhyay U ( 2004) Neem (Azadirachtaindica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma
Author(s): Udeinya IJ,Shu EN, Quakyi I,Ajayi FO
Author(s): Othman F, Motalleb G,Peng SLT,Rahmat A, Fakurazi S, et al.
Author(s): Srivastava P, Yadav N, Lella R,Schneider A, Jones A, et al.
Author(s): Kavitha K, Priyadarsini RV, Anitha P, Ramalingam K,Sakthivel R, et al.
Author(s): Elumalai P, Gunadharini DN,Senthilkumar K, Banudevi S,Arunkumar R, et al.
Author(s): Sharma C, Andrea J, Goala P, Taher MG,Tahir AR, et al.
Author(s): Dale PS, Tamhankar CP, George D, Daftary GV ( 2001) Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects
Author(s): Popiela T, Kulig J, Hanisch J, Bock PR
Author(s): Tong-PengXu, HuaShen, Ling-Xiang Liu, Yong-QianShu
Author(s): Hsu YL, Cho CY, Kuo PL
Author(s): Kawiak A, Zawacka-Pankau J, Lojkowska E
Author(s): Liu X, Cai W, Niu M, Chong Y, Liu H, et al.
Author(s): Santosh KS, Haruyo I, Gautam S, Ahn-Kwang-Seok, Bharat BA
Author(s): Chen CA, Chang HH, Kao CY, Tsai TH, Chen YJ
Author(s): Prashar R, Kumar A, Banerjee S,Rao AR
Author(s): Prashar R, Kumar A, Hewer A, Cole KJ, Davis W
Author(s): Aruna K,Sivaramakrishnan VM
Author(s): Aruna K, Sivaramakrishnan VM
Author(s): Ganasoundari A, Uma Devi P,Rao BS
Author(s): Leyon PV, Kuttan G
Author(s): Singh N, Singh SM, Shrivastava P
Author(s): Singh SM, Singh N, Shrivastava P
Author(s): Kuo CL, Chou CC, Yung BY
Author(s): Ali H, Dixit S
Author(s): Pahadiya S, Sharma J
Author(s): Ueda JY, Tezuka Y, Banskota AH, Le Tran Q, Tran QK, et al.
Author(s): Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, et al.
Author(s): Renault JH, Nuzillard JM, Le Crouérour G, Thépenier P, Zèches-Hanrot M, et al.
